# Retatrutide FAQ — prescriptions, compounding, side effects, and what the trials show

> Honest answers to the questions readers ask about retatrutide: can it be prescribed, when might it be approved, what do the trials show, what are the side effects, and how it compares with other incretin-pathway molecules.

Prescribing, compounding, timing of likely approval, side effects, comparison with other incretin molecules. Every answer is grounded in the published trial record.

## Can a doctor prescribe retatrutide for me today?

No. As of mid-2026, retatrutide is investigational. It has not been approved by the FDA, the EMA, the MHRA, or any other regulatory authority for any indication. There is no labeled product, no prescriber's information, no pharmacy SKU, and no insurance code. A clinician who wrote a prescription for retatrutide today would have nothing to prescribe — there is no commercial product to be dispensed.

The Phase 3 TRIUMPH program is still reading out [15]. TRIUMPH-1 reported topline results in 2026 [5] and TRIUMPH-4 in 2025 [6], but the regulatory submission process typically follows the full pivotal package, including the cardiovascular outcomes trial. Once a New Drug Application is filed, FDA review takes roughly 10 months under standard review and 6 months under priority review. A realistic earliest US availability window is therefore well after 2026.

## What about compounding pharmacies — can they make it?

No, not under either of the regulatory pathways that compounding pharmacies use. The 503A pathway covers patient-specific compounding from approved bulk substances; retatrutide is not on the FDA's 503A bulk drug list. The 503B outsourcing-facility pathway is unavailable for active investigational drugs being studied by their sponsor. Compounding retatrutide on either pathway would not be lawful in the United States.

The broader pattern with active investigational sponsor-controlled molecules is that compounding-pharmacy supply does not appear during the pivotal trial period. Readers who encounter offers of compounded retatrutide should treat such offers with significant skepticism — the regulatory frame does not permit them.

## How does retatrutide differ from other incretin-pathway therapies?

The mechanistic difference is the third receptor. Approved or late-stage incretin molecules in the broader field activate either GLP-1 alone (mono-agonists) or GLP-1 and GIP together (dual agonists). Retatrutide adds glucagon-receptor agonism to that combination [1]. The glucagon arm contributes a hypothesized increase in resting energy expenditure and hepatic lipolysis, on top of the appetite-reduction and glucose-control effects shared with the broader class [11].

Cross-trial comparisons should be read with caution — different populations, durations, dose-escalation schedules. The Phase 2 obesity trial reported 24.2% mean weight loss at 48 weeks on 12 mg [1], and TRIUMPH-1 reported 28.3% at 80 weeks [5]. These exceed published Phase 3 readouts for dual-agonist molecules in comparable populations, but a head-to-head trial has not been published.

## What weight loss has been reported?

In the Phase 2 obesity trial (Jastreboff 2023, NEJM), the 12 mg arm reached 17.5% mean body-weight reduction at week 24 and 24.2% at week 48, against 2.1% on placebo [1]. The placebo-adjusted reduction at week 48 was approximately 22% [16].

In TRIUMPH-1 (the Phase 3 obesity trial in adults without diabetes, n=2,339), the 12 mg arm reached 28.3% mean weight loss at week 80, with 45.3% of participants achieving at least 30% body-weight reduction; an extension cohort restricted to baseline BMI ≥35 reached 30.3% at week 104 [5].

In TRIUMPH-4 (the Phase 3 obesity-with-knee-osteoarthritis trial, n=445), the 12 mg arm reached 28.7% mean weight loss at week 68 [6].

## What about HbA1c and type 2 diabetes?

The Phase 2 type-2-diabetes trial (Rosenstock 2023, Lancet) enrolled 281 adults with baseline mean HbA1c of 8.3% [2]. The 12 mg arm reduced HbA1c by 2.02 percentage points over 36 weeks. Placebo moved 0.01 points. The dulaglutide 1.5 mg active comparator reduced HbA1c by 1.41 points. Up to 71% of participants on 12 mg reached HbA1c below 5.7% (the threshold for non-diabetic glycemia), and up to 82% reached HbA1c below 6.5% (the diagnostic threshold for diabetes) [17].

The Phase 3 TRANSCEND program covers type 2 diabetes endpoints in larger populations and has not yet read out [15].

## What does it do to liver fat?

A Phase 2a substudy published in Nature Medicine in 2024 examined retatrutide in 98 adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), measured by MRI proton-density fat fraction over 48 weeks [3]. The 12 mg arm produced an 86.0% mean relative reduction in liver fat content. Ninety-three percent of participants reached normalization (defined as hepatic fat fraction below 5%). Zero percent of placebo participants reached normalization.

A dedicated MASH-focused Phase 3 trial is enrolling within the broader TRIUMPH program [15].

## What are the most common side effects?

Gastrointestinal — nausea, diarrhea, vomiting, constipation — particularly during dose escalation [8]. Nausea incidence reached approximately 60% on the 12 mg arm of the Phase 2 obesity trial. Most events were mild to moderate and resolved as participants reached their maintenance dose.

Heart rate rose by approximately 5 to 10 beats per minute in a dose-dependent pattern, peaking around week 24 and declining partially thereafter [9]. Blood pressure fell — by up to 14.0 mmHg systolic on the 12 mg arm of TRIUMPH-4 over 68 weeks [6]. Cutaneous dysesthesia (skin tingling or burning) was reported in approximately one in five participants on 12 mg in TRIUMPH-4 and at lower frequency on 9 mg [14].

## What is dysesthesia, and should it worry me?

Dysesthesia is the medical term for an abnormal, often unpleasant sensation in the skin — tingling, burning, or prickling — that is not provoked by an obvious external trigger. In TRIUMPH-4 it appeared in roughly 20% of participants on the 12 mg arm and at lower frequency on 9 mg [14]. Events were generally mild and self-limited.

It is a distinctive signal: dysesthesia at this frequency has not been characteristic of mono- or dual-agonist incretin molecules in the broader class. Whether it is mechanistically tied to glucagon-receptor agonism, to the higher dose ceiling, or to something else is under investigation. For readers, the practical point is that it is one of the data points reviewers will weigh when retatrutide reaches regulatory submission.

## When might retatrutide be approved?

The publicly available answer is: not before the Phase 3 program completes a pivotal package and the sponsor files a New Drug Application. TRIUMPH-1 and TRIUMPH-4 have reported topline results [5][6]; other TRIUMPH trials and the cardiovascular outcomes trial (TRIUMPH-Outcomes, approximately 10,000 participants) are still reading out [15]. NDA filing typically follows a full pivotal package. After filing, FDA review takes roughly 10 months under standard review or 6 months under priority review.

Any specific approval date prior to that timeline is speculation. Sites that quote a particular month or quarter for retatrutide approval are extrapolating from press-release language.

## Is retatrutide on the WADA prohibited list?

Peptide hormones with insulinotropic and metabolic-modifying activity are addressed in WADA Code categories S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and S4 (Hormone and Metabolic Modulators). Athletes and anti-doping-tested individuals should consult the current WADA Prohibited List and their sport's anti-doping authority for explicit guidance before any exposure. Specific listing language for a given molecule can change between annual revisions of the list.

## How does retatrutide compare with dual GLP-1/GIP agonists?

Dual GLP-1/GIP agonists are already in clinical use as approved products for type 2 diabetes and obesity (named by their International Nonproprietary Names, not by any brand). Mechanistically, retatrutide adds a third receptor — glucagon — to that combination [1][11]. In preclinical models, triple agonism produced greater weight reduction and higher resting energy expenditure than dual agonism in the same lab [11]. In humans, cross-trial comparisons favor retatrutide on magnitude of weight loss [1][5], but no head-to-head trial has been published, and dose-escalation schedules differ between molecules. Direct comparison will require either a head-to-head trial or careful adjustment for population and protocol differences.

## Is research-chemical retatrutide sold online the same as the clinical-trial material?

No assurance that it is. Material sold outside clinical-trial supply chains has unverified identity, purity, and sterility. Buyers cannot independently confirm what is in the vial without analytical testing that most buyers do not perform. Even when a peptide labeled as retatrutide actually contains the correct sequence, manufacturing conditions, endotoxin levels, residual solvents, and stability over storage are not knowable from a vendor label.

This site does not sell retatrutide, does not refer to vendors that do, and does not endorse the use of research-chemical material for any purpose other than what its label permits.

## What is the half-life and how often is it dosed in trials?

The terminal elimination half-life is approximately 6 days in healthy human volunteers, established in the Phase 1 first-in-human study [7]. All trials have used once-weekly subcutaneous administration. Steady-state plasma concentrations are reached after approximately four weekly doses, which is why clinical effects typically consolidate around the four-to-eight-week mark.

## Who runs this site, and is it affiliated with the manufacturer?

Retatrutide Prescribed is an independent editorial publisher of summaries of the peer-reviewed research literature on retatrutide. The publisher is not a clinic, does not employ clinicians, does not provide medical advice, does not manufacture or sell any product, and is not affiliated with Eli Lilly or any other manufacturer, pharmacy, telehealth provider, or research-chemical vendor. See /about for more on editorial standards and sourcing.

---

An independent editorial reading of one investigational molecule — not a clinic, not a vendor, not a prescription.